Table 2. Biochemistry and virology evaluation.
| Group | n | ALT (IU/L) | ALB (g/L) | TBIL (µmol/L) | PT (s) | HBV DNA (x107copies/ml) | |
|---|---|---|---|---|---|---|---|
| Treated | Baseline | 32 | 75.7±18.5 | 34.9±4.4 | 39.3±21.2 | 15.2±3.4 | 4.5±2.7 |
| Week 4 | 32 | 37.3±16.3* | 38.2±5.9* | 17.1±9.5** | 13.2±2.1* | 4.4±2.4 | |
| Controls | Baseline | 28 | 83.3± 11.4 | 35.1±4.8 | 38.2±25.4 | 15.0±3.5 | 4.3±2.5 |
| Week 4 | 28 | 35.2±18.6* | 38.3±6.1* | 17.6±8.1* | 13.1±1.9* | 4.4±2.3 | |
Data are expressed as mean ± SD. Fisher’s exact test, EGb 761 versus Control. NS, not significant (P>0.05). Comparisons of blood levels of ALT, TBil, PT, ALB, and HBV DNA titres between baseline and after treatment in the same group; and comparisons inter-groups. ALT, alanine aminotransferase; TBIL, total bilirubin; ALB, albumin; PT, prothrombin. *P<0.05 VS baseline, **P<0.01 VS baseline